Back to search

Article

Title of the paper: Panobinostat (LBH589) increase survival in adult xenografic model of Acute Lymphoblastic Leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP

2022-05-11

Abstract excerpt

<title>Abstract</title> <p>Patients diagnosed with acute lymphoblastic leukemia (ALL) bearing t(4;11)/MLL-AF4 have aggressive clinical features, poor prognosis and there’s an urgent need for new therapies to improve outcomes. Panobinostat (LBH589) has been identified as a potential therapeutic agent for ALL with t(4;11) and studies suggest that the antineoplastic effects is associated with reduced MLL-AF4 fusion...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
22491ffb-a322-5edd-a36b-49176be2a92a
DOI
10.21203/rs.3.rs-1594461/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Title of the paper: Panobinostat (LBH589) increase survival in adult xenografic model of Acute Lymphoblastic Leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MPDOI 10.21203/rs.3.rs-1594461/v1
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.Semantic proximity
The Role of Genetics and Synergistic Effect of Targeting Common Genetic Mutations in Acute Lymphoblastic Leukemia (ALL).Semantic proximity
Clinical Characteristics and Outcome After Induction of Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: A Descriptive and Correlational Study From the West Bank of PalestineSemantic proximity
HDAC Inhibitor Vorinostat and BET Inhibitor Plx51107 Epigenetic Agents’ Combined Treatments Exert a Therapeutic Approach Upon Acute Myeloid Leukemia Cell ModelSemantic proximity
Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia ProgressionSemantic proximity
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.Semantic proximity
Promising Anti-leukemic Effect of Zataria Multiflora Extract in Combination with Doxorubicin to Combat Acute Lymphoblastic Leukemia Cells (Nalm-6)Semantic proximity
Patient-Derived Intrafemoral Orthotopic Xenografts of Peripheral Blood or Bone Marrow from Acute Myeloid and Acute Lymphoblastic Leukemia Patients: Clinical Characterization, Methodology, and ValidationSemantic proximity
Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AMLSemantic proximity
Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemiaSemantic proximity
Efficacy evaluation of glasedgib Sonic Hedgehog pathway inhibition with or without inotuzumab in B-ALL cells using a new co-culturing system model and a validated chemosensitivity assaySemantic proximity
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonistsSemantic proximity
Select a neighboring publication to make it the new centre.